NeOnc Technologies Holdings, Inc. Common Stock
NTHINeOnc Technologies Holdings, Inc. is a healthcare-focused company specializing in the development and commercialization of innovative diagnostic and therapeutic solutions for cancer. The company aims to leverage advanced technologies to improve cancer detection and treatment, providing targeted options to enhance patient outcomes.
Company News
NeOnc Technologies revealed preclinical research demonstrating that ultrasound can enhance the therapeutic potency of NEO100 for treating primary and metastatic brain tumors, using an AI-driven 3D-bioprinted methodology.
NeOnc Technologies will host an investor conference call to present data updates from its ongoing Phase 1/2a NEO100-1 clinical trial, focusing on intranasal delivery of NEO100 for treating recurrent high-grade malignant glioma.
NeOnc Technologies' subsidiary NuroMENA signed a Master Services Agreement with IROS, part of M42, to accelerate clinical cancer therapy development in the Middle East. The company also expanded its NuroMENA board by adding members from Quazar Investment.
NeOnc Technologies has appointed renowned neuro-oncologist Dr. Henry S. Friedman to its scientific advisory board, strengthening its expertise in developing therapies for central nervous system cancers.
NeOnc Technologies acquired an intellectual property portfolio featuring AI, 3D bioprinting, and quantum modeling technologies for $3.5 million, enhancing its drug discovery capabilities for central nervous system cancer therapies. Dr. Ishwar K. Puri was appointed to the company's Board of Directors.
